A Study of Vinblastine and Temsirolimus in Pediatric Patients with Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2019
Price : $35 *
At a glance
- Drugs Temsirolimus (Primary) ; Vinblastine (Primary)
- Indications Hodgkin's disease; Lymphoproliferative disorders; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- 16 Jan 2019 Status changed from active, no longer recruiting to completed.
- 31 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Mar 2016 Planned End Date changed from 1 Feb 2019 to 1 May 2020 as per ClinicalTrials.gov record.